Poziotinib

DB12114InvestigationalSmall molecule

Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among...

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₃H₂₁Cl₂FN₄O₃ · 491.34 g/mol (avg)
Code names: HM781-36 · HM 781-36B · NOV120101

Resolves to

Compound

UNIIOEI6OOU6IKCAS1092364-38-9ChEMBLCHEMBL3545154PubChem25127713

Structure

InChIKeyLPFWVDIFUFFKJU-UHFFFAOYSA-NSMILESCOC1=C(OC2CCN(CC2)C(=O)C=C)C=C2C(NC3=CC=C(Cl)C(Cl)=C3F)=NC=NC2=C1

Targets

P00533EGFRP04626ERBB2

What you can answer from here — as of May 26, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

21Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Poziotinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account